Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients

Thoracic Cancer
Ayako ShionoHiroshi Kagamu

Abstract

It is unclear whether the chemotherapy response improves after exposure to immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects that stimulate tumor shrinkage. We conducted a retrospective study to evaluate improvement of the efficacy of ramucirumab plus docetaxel after the failure of nivolumab as a PD-1 inhibitor. From February 2016 to December 2017, 152 patients with non-small cell lung cancer (NSCLC) administered nivolumab in our institution were identified. We reviewed the records of 20 NSCLC patients administered ramucirumab plus docetaxel after nivolumab failure. The overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were investigated. Pegylated granulocyte colony-stimulating factor was prophylactically administered to 18 patients (90%) after the administration of ramucirumab plus docetaxel. The median age of the patients was 70 (range: 55-77) years. Twelve patients were male and eight were female. The histology was adenocarcinoma in 16 patients, squamous cell carcinoma in three, and other in one. The ORR of ramucirumab plus docetaxel was 60%, and the PFS and OS were 169 and 343 days, respectively. Among the 20 patients, 12 a...Continue Reading

References

Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Feb 21, 2013·Cancer Immunology, Immunotherapy : CII·Rupal Ramakrishnan, Dmitry I Gabrilovich
Nov 26, 2014·Journal of the National Cancer Institute·Ken Garber
May 6, 2015·Cancer Immunology Research·Leisha A Emens, Gary Middleton
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Oct 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christian ManegoldEverett Vokes
Apr 14, 2017·Science Translational Medicine·Elizabeth AllenGabriele Bergers
Oct 25, 2017·Thoracic Cancer·Daiki OgawaraHiroshi Mukae
Nov 5, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Song Ee ParkJong-Mu Sun
Dec 2, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Gustavo SchvartsmanWilliam N William
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer

❮ Previous
Next ❯

Citations

Mar 3, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Jingxing Yang, Chunfu Zhang
Jul 17, 2020·Therapeutic Advances in Medical Oncology·Robert J Walsh, Ross A Soo
Aug 2, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·D IslaJ M Trigo
Nov 27, 2020·Japanese Journal of Clinical Oncology·Akihito KawazoeMasanori Terashima
Aug 7, 2021·Journal of Cancer Research and Clinical Oncology·Fen WangShubin Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.